BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 34580055)

  • 1. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial.
    Tsoukas MA; Majdpour D; Yale JF; Fathi AE; Garfield N; Rutkowski J; Rene J; Legault L; Haidar A
    Lancet Digit Health; 2021 Nov; 3(11):e723-e732. PubMed ID: 34580055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simple meal announcements and pramlintide delivery versus carbohydrate counting in type 1 diabetes with automated fast-acting insulin aspart delivery: a randomised crossover trial in Montreal, Canada.
    Cohen E; Tsoukas MA; Legault L; Vallis M; Von Oettingen JE; Palisaitis E; Odabassian M; Yale JF; Garfield N; Gouchie-Provencher N; Rutkowski J; Jafar A; Ghanbari M; Haidar A
    Lancet Digit Health; 2024 Jul; 6(7):e489-e499. PubMed ID: 38906614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alleviating carbohydrate counting with a FiASP-plus-pramlintide closed-loop delivery system (artificial pancreas): Feasibility and pilot studies.
    Tsoukas MA; Cohen E; Legault L; von Oettingen JE; Yale JF; Vallis M; Odabassian M; El Fathi A; Rutkowski J; Jafar A; Ghanbari M; Gouchie-Provencher N; René J; Palisaitis E; Haidar A
    Diabetes Obes Metab; 2021 Sep; 23(9):2090-2098. PubMed ID: 34047449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial.
    Haidar A; Tsoukas MA; Bernier-Twardy S; Yale JF; Rutkowski J; Bossy A; Pytka E; El Fathi A; Strauss N; Legault L
    Diabetes Care; 2020 Mar; 43(3):597-606. PubMed ID: 31974099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study.
    Boughton CK; Hartnell S; Thabit H; Poettler T; Herzig D; Wilinska ME; Ashcroft NL; Sibayan J; Cohen N; Calhoun P; Bally L; Mader JK; Evans M; Leelarathna L; Hovorka R
    Diabetes Obes Metab; 2021 Jun; 23(6):1389-1396. PubMed ID: 33606901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flexible insulin therapy with a hybrid regimen of insulin degludec and continuous subcutaneous insulin infusion with pump suspension before exercise in physically active adults with type 1 diabetes (FIT Untethered): a single-centre, open-label, proof-of-concept, randomised crossover trial.
    Aronson R; Li A; Brown RE; McGaugh S; Riddell MC
    Lancet Diabetes Endocrinol; 2020 Jun; 8(6):511-523. PubMed ID: 32445738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6-12 years: a randomised, controlled, cross-over, non-inferiority trial.
    Kariyawasam D; Morin C; Casteels K; Le Tallec C; Sfez A; Godot C; Huneker E; Garrec N; Benhamou PY; Polak M; Charpentier G; Franc S; Beltrand J
    Lancet Digit Health; 2022 Mar; 4(3):e158-e168. PubMed ID: 35216750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study.
    Thabit H; Lubina-Solomon A; Stadler M; Leelarathna L; Walkinshaw E; Pernet A; Allen JM; Iqbal A; Choudhary P; Kumareswaran K; Nodale M; Nisbet C; Wilinska ME; Barnard KD; Dunger DB; Heller SR; Amiel SA; Evans ML; Hovorka R
    Lancet Diabetes Endocrinol; 2014 Sep; 2(9):701-9. PubMed ID: 24943065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
    Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.
    Tauschmann M; Thabit H; Bally L; Allen JM; Hartnell S; Wilinska ME; Ruan Y; Sibayan J; Kollman C; Cheng P; Beck RW; Acerini CL; Evans ML; Dunger DB; Elleri D; Campbell F; Bergenstal RM; Criego A; Shah VN; Leelarathna L; Hovorka R;
    Lancet; 2018 Oct; 392(10155):1321-1329. PubMed ID: 30292578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study.
    Bally L; Thabit H; Kojzar H; Mader JK; Qerimi-Hyseni J; Hartnell S; Tauschmann M; Allen JM; Wilinska ME; Pieber TR; Evans ML; Hovorka R
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):261-270. PubMed ID: 28094136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study protocol for a randomised open-label clinical trial examining the safety and efficacy of the Android Artificial Pancreas System (AAPS) with advanced bolus-free features in adults with type 1 diabetes: the 'CLOSE IT' (Closed Loop Open SourcE In Type 1 diabetes) trial.
    Wilkinson T; Tomic D; Boyle E; Burren D; Elghattis Y; Jenkins A; Keesing C; Middleton S; Nanayakkara N; Williman J; de Bock M; Cohen ND
    BMJ Open; 2024 Feb; 14(2):e078171. PubMed ID: 38382954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.
    Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R
    CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies.
    Hovorka R; Kumareswaran K; Harris J; Allen JM; Elleri D; Xing D; Kollman C; Nodale M; Murphy HR; Dunger DB; Amiel SA; Heller SR; Wilinska ME; Evans ML
    BMJ; 2011 Apr; 342():d1855. PubMed ID: 21493665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing the need for carbohydrate counting in type 1 diabetes using closed-loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non-inferiority, crossover pilot trial.
    Haidar A; Yale JF; Lovblom LE; Cardinez N; Orszag A; Falappa CM; Gouchie-Provencher N; Tsoukas MA; El Fathi A; Rene J; Eldelekli D; Lanctôt SO; Scarr D; Perkins BA
    Diabetes Obes Metab; 2021 Jun; 23(6):1272-1281. PubMed ID: 33528904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.
    Kropff J; Del Favero S; Place J; Toffanin C; Visentin R; Monaro M; Messori M; Di Palma F; Lanzola G; Farret A; Boscari F; Galasso S; Magni P; Avogaro A; Keith-Hynes P; Kovatchev BP; Bruttomesso D; Cobelli C; DeVries JH; Renard E; Magni L;
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):939-47. PubMed ID: 26432775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.
    El-Khatib FH; Balliro C; Hillard MA; Magyar KL; Ekhlaspour L; Sinha M; Mondesir D; Esmaeili A; Hartigan C; Thompson MJ; Malkani S; Lock JP; Harlan DM; Clinton P; Frank E; Wilson DM; DeSalvo D; Norlander L; Ly T; Buckingham BA; Diner J; Dezube M; Young LA; Goley A; Kirkman MS; Buse JB; Zheng H; Selagamsetty RR; Damiano ER; Russell SJ
    Lancet; 2017 Jan; 389(10067):369-380. PubMed ID: 28007348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial.
    Daly AB; Boughton CK; Nwokolo M; Hartnell S; Wilinska ME; Cezar A; Evans ML; Hovorka R
    Nat Med; 2023 Jan; 29(1):203-208. PubMed ID: 36631592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes.
    Ware J; Allen JM; Boughton CK; Wilinska ME; Hartnell S; Thankamony A; de Beaufort C; Schierloh U; Fröhlich-Reiterer E; Mader JK; Kapellen TM; Rami-Merhar B; Tauschmann M; Nagl K; Hofer SE; Campbell FM; Yong J; Hood KK; Lawton J; Roze S; Sibayan J; Bocchino LE; Kollman C; Hovorka R;
    N Engl J Med; 2022 Jan; 386(3):209-219. PubMed ID: 35045227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial.
    Benhamou PY; Franc S; Reznik Y; Thivolet C; Schaepelynck P; Renard E; Guerci B; Chaillous L; Lukas-Croisier C; Jeandidier N; Hanaire H; Borot S; Doron M; Jallon P; Xhaard I; Melki V; Meyer L; Delemer B; Guillouche M; Schoumacker-Ley L; Farret A; Raccah D; Lablanche S; Joubert M; Penfornis A; Charpentier G;
    Lancet Digit Health; 2019 May; 1(1):e17-e25. PubMed ID: 33323237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.